Action IMNM IMMUNOME, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Immunome, Inc.

Actions

IMNM

US45257U1088

Temps réel estimé Cboe BZX
Autres places de cotation
 18:43:53 11/06/2024 		Varia. 5j. Varia. 1 janv.
15,5 USD -3,40 % Graphique intraday de Immunome, Inc. +8,90 % +44,11 %
31/05 IMMUNOME, INC. : Piper Sandler persiste à l'achat ZM
21/05 Un initié d'Immunome a acheté des actions d'une valeur de 1 388 072 $, selon un récent dépôt auprès de la SEC MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing
Immunome Completes Purchase of Antibodies From Atreca
Immunome Promotes Max Rosett to Chief Financial Officer
Immunome Announces Completion of Purchase of Assets from Atreca
Immunome, Inc. completed the acquisition of Substantially all Assets of Atreca, Inc..
Immunome Appoints Max Rosett as CFO
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
Immunome, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Certain Common Stock of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.
Certain Warrants of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.
Certain Stock Options of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.
Immunome to Present at 2024 Bank of America Healthcare Conference
Immunome Appoints Kinney Horn as Chief Business Officer
Immunome, Inc. Appoints Kinney Horn as Chief Business Officer
Immunome, Inc. Announces Executive Changes
Immunome Appoints Sandra M. Swain to Board of Directors
Immunome, Inc. Appoints Sandra M. Swain to Board of Directors
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research Annual Meeting
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action IMNM
  4. Actualités Immunome, Inc.
  5. Autres langues